IMCC
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
P/B of -0.80 indicates the company's liabilities exceed its assets.
- Very low P/S ratio
- Negative P/B ratio
- No Graham Number possible due to negative earnings
Growth is present but insufficient to offset structural losses.
- 17.6% Revenue growth
- Recent EPS surprise beats
- Negative operating margins
- No clear path to profitability
Historical price performance is among the worst in the sector.
- 5Y Change: -99.9%
- 1Y Change: -72.7%
- Consistent history of massive EPS misses
Piotroski score is marginally stable, but balance sheet metrics suggest imminent distress.
- Piotroski F-Score of 4/9 (Stable)
- Current Ratio < 1.0
- Negative Equity
- Negative ROA
Dividend strength is 0/100.
- No dividend paid
- No capacity for dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for IMCC and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
IMCC
IM Cannabis Corp.
Primary
|
-99.9% | -91.4% | -72.7% | -81.3% | -57.0% | +6.5% |
|
INM
InMed Pharmaceuticals Inc.
Peer
|
-100.0% | -97.1% | -71.7% | -66.3% | -10.5% | +5.6% |
|
HCWB
HCW Biologics Inc.
Peer
|
-99.9% | -99.4% | -96.3% | -91.0% | -30.6% | +36.0% |
|
BDRX
Biodexa Pharmaceuticals Plc
Peer
|
-100.0% | -100.0% | -95.1% | -75.6% | -24.0% | -4.0% |
|
AKAN
Akanda Corp.
Peer
|
-100.0% | -100.0% | -96.4% | -95.4% | -13.6% | -6.7% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q2 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
IMCC
IM Cannabis Corp.
|
BEARISH | $2.25M | - | -% | -20.7% | $0.36 | |
|
INM
InMed Pharmaceuticals Inc.
|
BEARISH | $2.37M | - | -97.2% | -170.1% | $0.72 | Compare |
|
HCWB
HCW Biologics Inc.
|
BEARISH | $2.45M | - | -% | -% | $0.36 | Compare |
|
BDRX
Biodexa Pharmaceuticals Plc
|
BEARISH | $1.8M | - | -61.8% | -% | $2.15 | Compare |
|
AKAN
Akanda Corp.
|
BEARISH | $1.73M | 0.01 | -60.9% | -266.3% | $0.82 | Compare |
Past News Coverage
Recent headlines mentioning IMCC from our newsroom.